What the Study Found (In Plain English)
Published in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (2022), this phase iii randomized trial evaluating 202 human participants investigated: Pediatric functional constipation (PFC) is a common problem in children that causes distress and presents treatment challenges to health care professionals. Key clinical takeaway: Lubiprostone did not demonstrate statistically significant effectiveness over placebo in children and adolescents with PFC but did demonstrate a safety profile similar to that in adults.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022-03-15; N = 202; Rigor 88/100): Lubiprostone did not demonstrate statistically significant effectiveness over placebo in children and adolescents with PFC but did demonstrate a safety profile similar to that in adults.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.